Dividend Overview
Dividend Yield
—
Dividend / Share
—
Arvinas Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC ® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC ® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC ® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Did you know?
Holds 16.1x more cash than debt — a strong balance sheet.
Current Price
$10.51
+6.16%Profile
Valuation (TTM)
Market Cap$675.00M
P/E-8.35
EV—
P/B1.56
Shares Out64.22M
P/Sales2.57
Revenue$262.60M
EV/EBITDA—
Arvinas Inc (ARVN) Dividends
Key Metrics
Market Cap
$675.00M
P/E Ratio
-8.35
Forward P/E
—
EPS
$-1.14
PEG Ratio
-0.16
Book Value
$6.76
Dividend Yield
—
Profit Margin
-30.77%
ROE
-18.62%
Dividend History
Dividend Safety
ARVN Dividend Analysis
Arvinas Inc (ARVN) dividend analysis including yield, payout history, and sustainability metrics.
P/E ratio: -8.35. Profit margin: -30.77%. Free cash flow: $-275.70M. This page shows Arvinas Inc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.
GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Arvinas Inc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.